X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

New analysis: More than half of patients’ out-of-pocket spending for brand medicines is based on full list price

By Holly Campbell  |    March 29, 2017
More than half of commercially insured patients’ out-of-pocket spending for brand medicines is based on full list prices, according to a new analysis from Amundsen Consulting, a division of...   Read More

Resources for understanding the dangers of drug importation

By Nicole Longo  |    March 28, 2017
Recent proposals to allow drug importation from other countries are dangerous for patients and the U.S. drug supply chain. To better understand how these importation schemes could negatively...   Read More

ICYMI: Survey highlights key barriers limiting number and scale of new approaches to paying for medicines

By Michelle Drozd  |    March 27, 2017
In recent years we have seen remarkable scientific breakthroughs in the discovery of new therapies to treat some of the most challenging diseases faced by patients. These groundbreaking medicines...   Read More

Medicare Monday: A discussion on affordability and access to medicines

By Nicole Longo  |    March 27, 2017
In case you missed it, the American Society on Aging held its annual conference last week in Chicago, IL, where Lori Reilly, PhRMA executive vice president of policy, research & membership, spoke...   Read More

17 years (and more) of medical discoveries

By Priscilla VanderVeer  |    March 24, 2017
Someone asked me recently if donated kidneys last forever. It’s been 17 years and a few days since I received one, which has lasted 17 years longer than I thought it would. That may not be...   Read More

ICYMI: What the experts are saying about importation

By Allyson Funk  |    March 23, 2017
Voices throughout the U.S. and Canadian health care systems have raised concerns about proposed large-scale drug importation schemes. Former government officials, pharmacy groups and experts have...   Read More

Guest Post: The importance of a modern FDA in drug discovery

By Guest Contributor  |    March 22, 2017
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Medicare Monday: Billing code basics for biologics in Part B

By Allyson Funk  |    March 20, 2017
We’ve explored the Centers for Medicare & Medicaid Services’ (CMS) flawed policy for reimbursing biologic and biosimilar products before. Today, we’re exploring how proposals from MedPAC would...   Read More

How drug importation schemes could increase U.S. law enforcement burdens

By Allyson Funk  |    March 16, 2017
In recent weeks, we’ve explored some of the dangers of importation for patients and how medicines purchased online can be fake. But what would importation schemes mean for U.S. law enforcement?   Read More

Medicare Monday: A closer look at Part B spending

By Nicole Longo  |    March 13, 2017
Earlier this month, MedPAC discussed Part B drug spending growth but neglected to put this information in the context of overall program spending. Spending on Part B medicines continues to be a...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates